HK1219873A1 - 利用肝細胞生長因子的兩種以上的異構體的肌萎縮性側索硬化症預防或治療用組合物 - Google Patents

利用肝細胞生長因子的兩種以上的異構體的肌萎縮性側索硬化症預防或治療用組合物

Info

Publication number
HK1219873A1
HK1219873A1 HK16107864.0A HK16107864A HK1219873A1 HK 1219873 A1 HK1219873 A1 HK 1219873A1 HK 16107864 A HK16107864 A HK 16107864A HK 1219873 A1 HK1219873 A1 HK 1219873A1
Authority
HK
Hong Kong
Prior art keywords
isoforms
preventing
composition
growth factor
lateral sclerosis
Prior art date
Application number
HK16107864.0A
Other languages
English (en)
Inventor
鄭在均
Original Assignee
Viromed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/KR2014/009971 external-priority patent/WO2015060650A2/ko
Application filed by Viromed Co Ltd filed Critical Viromed Co Ltd
Publication of HK1219873A1 publication Critical patent/HK1219873A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16107864.0A 2013-10-22 2016-07-06 利用肝細胞生長因子的兩種以上的異構體的肌萎縮性側索硬化症預防或治療用組合物 HK1219873A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130126216 2013-10-22
PCT/KR2014/009971 WO2015060650A2 (ko) 2013-10-22 2014-10-22 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
HK1219873A1 true HK1219873A1 (zh) 2017-04-21

Family

ID=53386224

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107864.0A HK1219873A1 (zh) 2013-10-22 2016-07-06 利用肝細胞生長因子的兩種以上的異構體的肌萎縮性側索硬化症預防或治療用組合物

Country Status (13)

Country Link
US (1) US10639351B2 (zh)
EP (1) EP3061457B1 (zh)
JP (1) JP6240337B2 (zh)
KR (2) KR101779775B1 (zh)
CN (1) CN105682676B (zh)
AU (1) AU2014337870B2 (zh)
BR (1) BR112016008267A2 (zh)
CA (1) CA2926607C (zh)
ES (1) ES2773305T3 (zh)
HK (1) HK1219873A1 (zh)
MX (1) MX2016005006A (zh)
RU (1) RU2639582C2 (zh)
SG (1) SG11201602452SA (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046202B1 (fr) * 2015-12-24 2017-12-29 Snecma Turboreacteur avec un moyen de reprise de poussee sur le carter inter-compresseurs
EP3733855A4 (en) * 2017-12-29 2021-03-03 Helixmith Co., Ltd ADENO-ASSOCIATED VIRUS (AAV) VECTOR INCLUDING A HYBRID HGF GENE INTRODUCED INTO ITS BREAST
KR20210025122A (ko) * 2018-07-17 2021-03-08 주식회사 헬릭스미스 Igf-1-암호화 dna 작제물들 및 hgf-암호화 dna 작제물들을 사용한 신경병증 치료
CN110577954A (zh) * 2019-10-12 2019-12-17 北京万福来生物技术有限责任公司 突变的肝细胞生长因子基因及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0255320A3 (en) 1986-07-28 1989-09-06 Genzyme Corporation Production of proteins in myeloma cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2022752C (en) 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
JP2634323B2 (ja) 1990-07-13 1997-07-23 雪印乳業株式会社 Ｔｃｆ‐▲ｉｉ▼のアミノ酸配列をコードするｄｎａを含むプラスミド，形質転換細胞及びこれを用いて生理活性物質を生産する方法
US5661133B1 (en) 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US7323297B1 (en) 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5652225A (en) 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US6143714A (en) 1994-10-24 2000-11-07 Regeneron Pharmaceuticals, Inc. Methods of using hepatocyte growth factor to promote survival, growth and differentiation of motor neurons
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
US6248722B1 (en) 1995-08-29 2001-06-19 Sumitomo Pharmaceuticals Company, Limited Medicament comprising HGF gene
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
CA2289600C (en) 1997-05-06 2010-06-29 The Regents Of The University Of California Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
WO1999036103A1 (en) 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
JPH11246433A (ja) 1998-03-03 1999-09-14 Sumitomo Pharmaceut Co Ltd 心筋梗塞治療剤
CA2322559C (en) 1998-03-09 2012-07-17 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
US20040228834A1 (en) 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
AU765177B2 (en) 1998-03-13 2003-09-11 Wyeth Polynucleotide composition, method of preparation, and use thereof
DK1061955T3 (da) 1998-03-13 2005-07-04 Wyeth Corp Polynukleotidsammensætning, fremstillingsmetode og anvendelse deraf
US7276359B1 (en) 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
US6887477B1 (en) 1998-08-05 2005-05-03 Tomokazu Nagano Method of treating ischemic disease by intramuscular administration of Hepatocyte growth factor
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
EP1142590B8 (en) 1999-10-29 2008-11-26 AnGes MG, Inc. Gene therapy for diabetic ischemic disease
NZ546670A (en) 1999-11-05 2009-02-28 Univ California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
KR100798566B1 (ko) 2000-06-27 2008-01-28 안제스에무지 가부시키가이샤 혈관 신생요법용 의약조성물
AU2001286221B2 (en) 2000-09-13 2006-09-28 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
JP5442173B2 (ja) * 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤
US20030176347A1 (en) * 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
CN1150035C (zh) 2000-12-21 2004-05-19 中国人民解放军军事医学科学院放射医学研究所 一种重组质粒及其在疾病防治中的应用
JP2005501802A (ja) 2001-01-23 2005-01-20 ボストン　サイエンティフィック　コーポレイション 虚血心筋を処置するための限局性心筋注入方法
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
CA2508279A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US20050164208A1 (en) 2004-01-22 2005-07-28 Paul Poulin Storage of genetic information
KR100833612B1 (ko) * 2004-12-29 2008-05-30 에프씨비파미셀 주식회사 간엽 간세포로부터 분화된 신경세포를 유효성분으로함유하는 신경계 질환 치료용 약학 조성물
CA2603857A1 (en) 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US20070212390A1 (en) 2005-09-22 2007-09-13 Ludwig Institute For Cancer Research Protease-resistant forms of VEGF-D, method of making and method of use
JP2009515520A (ja) 2005-11-10 2009-04-16 レセプター バイオロジックス， インコーポレイテッド 肝細胞成長因子イントロン融合蛋白
CN101448939B (zh) 2006-05-17 2011-12-14 小山义之 用于导入核酸、寡核酸或其衍生物的冷冻干燥体
WO2007142651A1 (en) 2006-06-09 2007-12-13 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods and compositions for the treatment of neuropathy
ES2520044T3 (es) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
JP5248519B2 (ja) 2007-11-07 2013-07-31 小野薬品工業株式会社 Ｓｄｆ−１を含有してなる徐放性組成物
US20090202606A1 (en) 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
RU2470995C2 (ru) 2008-04-09 2012-12-27 Вайромед Ко., Лтд. Лиофилизированные днк-составы для увеличенной экспрессии плазмидной днк
RU2413524C1 (ru) * 2009-07-31 2011-03-10 Общество с ограниченной ответственностью "КриоЦентр" Способ лечения психических и неврологических расстройств
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
WO2013037521A1 (en) * 2011-09-16 2013-03-21 Medical Research Council Modified hgf-1k1 polypeptide
WO2013037520A1 (en) * 2011-09-16 2013-03-21 Glaxo Group Limited Modified hgf-1k1 polypeptide
JP2013129661A (ja) * 2013-02-20 2013-07-04 Toshiichi Nakamura 筋萎縮性側索硬化症治療剤

Also Published As

Publication number Publication date
KR20150047108A (ko) 2015-05-04
AU2014337870A1 (en) 2016-05-05
SG11201602452SA (en) 2016-05-30
US20160250291A1 (en) 2016-09-01
EP3061457B1 (en) 2020-01-22
KR20170104129A (ko) 2017-09-14
CN105682676B (zh) 2020-10-23
JP2016534149A (ja) 2016-11-04
US10639351B2 (en) 2020-05-05
KR101860452B1 (ko) 2018-05-24
RU2016119116A (ru) 2017-11-28
AU2014337870B2 (en) 2019-11-28
CA2926607C (en) 2018-10-23
RU2639582C2 (ru) 2017-12-21
BR112016008267A2 (pt) 2017-10-03
EP3061457A2 (en) 2016-08-31
EP3061457A4 (en) 2017-06-07
KR101779775B1 (ko) 2017-09-21
JP6240337B2 (ja) 2017-11-29
CN105682676A (zh) 2016-06-15
CA2926607A1 (en) 2015-04-30
MX2016005006A (es) 2016-07-14
ES2773305T3 (es) 2020-07-10

Similar Documents

Publication Publication Date Title
PL3030663T3 (pl) Kompozycje i sposoby kontroli leptinotarsa
EP3052632A4 (en) Compositions and methods for treating amyotrophic lateral sclerosis
EP2991953A4 (en) COMPOSITION FOR TREATING STONE AND METHOD FOR MANUFACTURING THE SAME
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
EP2950884A4 (en) COMPOSITIONS AND METHOD FOR TREATING SURFACES
EP2895606A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS (ALS)
IL244118B (en) A preparation containing dexpermipexole for the treatment of various types of urticaria
PL3021839T3 (pl) Kompozycje do leczenia zwłóknienia
HK1219873A1 (zh) 利用肝細胞生長因子的兩種以上的異構體的肌萎縮性側索硬化症預防或治療用組合物
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
EP2983789A4 (en) COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
PT3038596T (pt) Composições e métodos para a remoção de tatuagens
HRP20182110T1 (hr) Sastav spojeva tiakumicina
HK1220609A1 (zh) 種用於治療肌萎縮性側索硬化症的β受體阻滯劑的 -對映體富集組合物
ZA201507015B (en) Composition for treating hemorrhoids
HRP20181445T1 (hr) Sastavi i postupci za liječenje dijabetesa tipa 1
HK1204865A1 (zh) 消滅棘手的有害動物的組合物
ZA201408732B (en) Composition and methods for treating wounds
AU2013903871A0 (en) Compositions for treating skin conditions
GB201302474D0 (en) Compositions and methods for treating biofilms
GB201302472D0 (en) Compositions and methods for treating biofilms
GB201302475D0 (en) Compositions and methods for treating biofilms